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Abstract
Background: Coronavirus disease 2019 (COVID-19) continues to be a major global health
burden. This study aims to estimate the all-cause excess mortality occurring in the
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COVID-19 outbreak in Japan, 2020, by sex and age group.
Methods: Daily time series of mortality for the period January 2015–December 2020 in
all 47 prefectures of Japan were obtained from the Ministry of Health, Labour and
Welfare, Japan. A two-stage interrupted time-series design was used to calculate excess
mortality. In the first stage, we estimated excess mortality by prefecture using quasi-
Poisson regression models in combination with distributed lag non-linear models,
adjusting for seasonal and long-term variations, weather conditions and influenza activ-
ity. In the second stage, we used a random-effects multivariate meta-analysis to synthe-
size prefecture-specific estimates at the nationwide level.
Results: In 2020, we estimated an all-cause excess mortality of 20 982 deaths [95% em-
pirical confidence intervals (eCI): 38 367 to 5472] in Japan, which corresponded to a
percentage excess of 1.7% (95% eCI: 3.1 to 0.5) relative to the expected value.
Reduced deaths were observed for both sexes and in all age groups except those aged
<60 and 70–79 years.
Conclusions: All-cause mortality during the COVID-19 outbreak in Japan in 2020 was de-
creased compared with a historical baseline. Further evaluation of cause-specific excess
mortality is warranted.
Key words: All-cause death, COVID-19, excess mortality, Japan, two-stage interrupted time-series design
Introduction
Since the early reports of an outbreak of severe acute respi-
ratory syndrome coronavirus 2 (SARS-CoV-2) in Wuhan,
China, in December 2019, coronavirus disease 2019
(COVID-19) has had global impact, resulting in consider-
able morbidity, mortality and economic burden.1 As of 24
March 2021, the global number of confirmed cases of
COVID-19 across the globe stood at 123 902 242, includ-
ing 2 727 837 deaths.2,3
Estimation of the excess deaths resulting from COVID-
19 is an important challenge since it quantifies the overall
burden of COVID-19 compared with a baseline level.4
Several studies have reported significant excess COVID-19
mortality in the USA and European countries.4–11 However,
despite early exposure, high population density and ageing,
and no strict quarantine or lockdown measures, Japan has
had one of the lowest number of COVID-19 deaths in the
world.12 Although several studies have reported excess mor-
tality during the COVID-19 epidemic in Japan,13,14 these
analyses were based on monthly or weekly data on shorter
periods (from January to May or July 2020), used different
reference periods (mean monthly mortality in 2 years or
3 weeks before and after a certain point for 5 years ago)
and did not adjust for seasonal influenza activity, ambient
temperature and temporal trends and variations in these
confounding factors. The pandemic of COVID-19 is ongo-
ing and it is difficult to cover the entire pandemic in Japan.
However, to gain a better understanding of the impact of
the disease on mortality in Japan, use of more detailed data
over a longer period is essential. Additionally, few studies
have accounted for weather factors, influenza epidemics,
seasonality and long-term trends. These potential biases
might affect interpretation of the results and resolving them
requires quantification of excess mortality using more pre-
cise modelling methods. Understanding patterns of excess
mortality in Japan offers an opportunity to identify whether
Japan’s unique approach to COVID-19 control, based on
limited voluntary lockdowns and case isolation following
Key Messages
• We estimated the all-cause excess mortality occurring in the COVID-19 outbreak in Japan in 2020 by sex and age
group.
• In 2020, we estimated an all-cause excess mortality of 20 982 deaths in Japan, which corresponded to a percentage
excess of 1.7% relative to the expected value.
• Reduced deaths were observed for both sexes and in all age groups except those aged <60 and 70–79 years.
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World Health Organization (WHO) guidelines, is associated
with a different pattern of mortality than the approach in
hard-hit nations.
Here, we examined overall excess mortality in the
COVID-19 outbreak across all 47 prefectures in Japan, with
stratification by sex and age group. Assessment of excess
mortality was based on official mortality data obtained
from the Ministry of Health, Labour and Welfare, Japan.
Methods
Data
We obtained the number of daily deaths, with stratification
by sex and age group in 2015–2020 in all 47 prefectures of
Japan from the Ministry of Health, Labour and Welfare.
The data included complete daily totals for 2015–2019
and early-release data of 2020. Vital statistics in Japan are
surveyed based on the Family Register Act and all registries
of vital statistics are thought to be complete. We also
obtained data on average daily temperatures in 2015–2020
from the Japan Meteorological Agency.15 For this, data
were sourced from one weather station within an urban re-
gion of each prefectural capital city. Measurements were
made hourly across 24 hours and averaged to yield average
daily temperatures. Furthermore, we obtained national
surveillance data on weekly influenza cases in 2015–2020
in all 47 Japanese prefectures from the National Institute
of Infectious Diseases.16 The daily number of influenza
cases was calculated by converting weekly surveillance
data to daily values using a uniform distribution of events
over 1 week. Mortality counts were summed by prefecture
in a sex- and age-specific daily time series and were then
associated with daily mean temperature and incidence of
influenza cases.
Statistical analysis
We used a two-stage interrupted time-series design to esti-
mate the time-varying excess mortality in Japan during the
COVID-19 outbreak in comparison with the pre-outbreak
period, which accounted for temporal trends and varia-
tions in other risk factors, as detailed elsewhere.10 In the
first stage, we used a quasi-Poisson-regression model:17
log E Yitð Þ½  ¼ aþ h1 days from first COVID19 case; hið Þ
þ dateþ h2 day of the year; ci
 
þ dow




where Yit denotes daily deaths observed at time t in prefec-
ture i.
The first component h1 (days from first COVID19 case;
hi) represents the spline function that models temporal ex-
cess mortality associated with the COVID-19 outbreak
and was defined using a constrained quadratic B-spline sys-
tem. Three equally spaced knots were used in the spline
terms to control the smoothness for days from 14 January
(date of first confirmed COVID-19 case) to 31 December
2020; the choice of the number of internal knots was based
on the smallest Quasi-Akaike Information Criterion (QAIC)
(Supplementary Table S9, available as Supplementary data
at IJE online).
To deal with time-varying confounders (or nuisance
variables), we included a linear term for date to control for
long-term trends, a cyclic cubic B-spline with 5 degrees of
freedom (df) for day of the year h2 day of the year; ci
 
to
account for seasonality, as well as dummy indicators for
the day of the week (dow) to control for weekly variation
in mortality. To control for potential differences in under-
lying mortality arising from the non-optimal temperature
between the pre-outbreak and outbreak periods, we model
the complex relationship between temperature and mortal-
ity characterized by non-linearity and delayed (lagged)
effects along the lag ‘ as a cross-basis term f Tit; ‘; bið Þ of
distributed lag non-linear models.18 In the cross-basis pa-
rameterization, we considered a natural cubic-spline func-
tion for the temperature with three internal knots, set at
the 10th, 75th and 90th percentiles of prefecture-specific
empirical distributions of the temperature and we consid-
ered the lags of 21 days to account for the delayed impact
of temperature.19 Influenza terms with lags of 14 days
(flu) were included to control for potential confounding of
influenza epidemics and their delayed effects.4,11 To allow
for autocorrelations, an autoregressive term of lagged




into the models.20 We checked the dispersion parameter
(average of 1.066 in our data), model residuals, observed
and fitted values, autocorrelation and partial autocorrela-
tion function of the residuals to determine adequate adjust-
ment for seasonal trends (Supplementary Figures S1–S4,
available as Supplementary data at IJE online).
In the second stage, we evaluated prefecture-based coef-
ficients hi that characterize the excess mortality during the
COVID-19 outbreak using a random-effects multivariate
meta-analysis model to synthesize the prefecture-specific
estimates of coefficients hi at the nationwide level.
21 We
then calculated the best linear unbiased prediction (BLUP)
estimated at the prefecture level ĥbi. The BLUP estimate
represents a trade-off between specific-to-prefecture and
pooled-among-prefectures associations, which enables
areas with small numbers of daily cases to use information
obtained from larger populations that share similar charac-
teristics and thus stabilizes the estimates.22 The Cochran’s
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Q test, which asymptotically follows the chi-squared distri-
bution with the df of 46, were used to assess the heteroge-
neity between prefectures. This approach has been widely
studied in the two-stage time-series design or individual pa-
tient data meta-analysis.21–24
Nationwide and prefecture-specific estimates were used
to calculate the relative risk (RR) of excess mortality in
each prefecture for every day of the outbreak period. In
particular, every day of the outbreak period was repre-
sented using the quadratic B-spline system and the nation-
wide and BLUP prefecture-specific estimates applied to the
spline values. The obtained predicted values were then
exponentiated obtaining the RR of excess mortality for ev-
ery day of the outbreak period. The daily number of excess
deaths was calculated as n*(RR-1)/RR, in which n is the
number of deaths per day. We calculated empirical confi-
dence intervals (eCIs) with 1000 Monte Carlo simulations
established using a multivariate normal distribution for the
BLUPs for the reduced coefficients. This approach has
been tested in a similar context before.18,23,25 Stratified
analysis was performed by sex and age groups (<60, 60–
69, 70–79, 80–89 and 90 years).
Statistical analyses were performed using the packages
dlnm and mvmeta in R 3.6.3 (R Core Team, R Foundation
for Statistical Computing, Vienna, Austria).
Results
Total deaths, estimated excess deaths and percentage ex-
cess in mortality during the period 13 February–31
December 2020 in Japan are summarized in Table 1. In
this period, 1 190 409 deaths were registered in Japan,
with an estimated excess of 20 982 deaths (95% eCI:
38 367 to 5472) relative to the expected baseline mor-
tality. This corresponds to a percentage excess of 1.7%
(95% eCI: 3.1 to 0.5), indicating that mortality was
slightly lower in 2020 than would have been expected
given national trends. Among the 47 prefectures, 46
prefectures had the negative percentage of total excess
mortality, with the exception of Hyogo Prefecture [0.2%
(95% eCI: 1.0 to 1.3)]. Descriptive statistics before and
during the COVID-19 pandemic by prefecture are reported
in Supplementary Table S1 (available as Supplementary
data at IJE online). The number of observed and estimated
excess deaths (95% eCI) during the period 13 February–31
December 2020 by prefecture is shown in Supplementary
Table S2 (available as Supplementary data at IJE online).
In the sex-stratified analysis, there were 8021 excess
deaths in men (95% eCI: 15 155 to 1779), correspond-
ing to a percentage excess of 1.3% (95% eCI: 2.4 to
0.3). The same estimate for women was 14 561 (95%
eCI: 19 506 to 9685), corresponding to a percentage
excess of 2.5% (95% eCI: 3.3 to 1.6).
In the age-stratified analysis, there were 2213 excess
deaths (95% eCI: 386 to 3895) in the <60-years age
group, 4662 (95% eCI: 7972 to 1492) in the 60– to
69-years age group, 4153 (95% eCI: 23 to 8080) in the
70– to 79-years age group, 11 995 (95% eCI: 18 517 to
6138) in the 80–to 89-years age group and 13 604
(95% eCI: 20 585 to 7189) in the 90-years age group.
The percentage of excess mortality was 3.1% (95% eCI:
0.5 to 5.6) in the <60-years age group, 4.5% (95% eCI:
7.5 to 1.5) in the 60– to 69-years age group, 1.7%
(95% eCI: 0.0 to 3.4) in the 70– to 79-years age group,
2.7% (95% eCI: 4.2 to 1.4) in the 80– to 89-years
age group and 3.8% (95% eCI: 5.7 to 2.1) in the
90-years age group.
Temporal changes in excess risk of mortality during the
period 14 January–31 December 2020 in Japan by sex and
age group are shown in Figure 1. We found that the total
excess risk of mortality started decreasing below the base-
line at the beginning of January and continued to remain
low. From around September, the total excess risk gradu-
ally started increasing and the peak was reached around
the beginning of November. The temporal distribution of
excess-mortality risk is consistent in both sex and age
Table 1 Number of observed and estimated excess deaths (95% empirical confidence interval) during the period 13 February–31
December 2020 in Japan
Total deaths Excess deaths Percentage excess
Total 1 190 409 20 982 (38 367 to 5472) 1.7 (3.1 to 0.5)
Sex Males 612 370 8021 (15 155 to 1779) 1.3 (2.4 to 0.3)
Females 578 039 14 561 (19 506 to 9685) 2.5 (3.3 to 1.6)
Age <60 73 688 2213 (386 to 3895) 3.1 (0.5 to 5.6)
60–69 98 152 4662 (7972 to 1492) 4.5 (7.5 to 1.5)
70–79 248 471 4153 (23 to 8080) 1.7 (0.0 to 3.4)
80–89 426 982 11 995 (18 517 to 6138) 2.7 (4.2 to 1.4)
90 343 116 13 604 (20 585 to 7189) 3.8 (5.7 to 2.1)
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groups, with an indication of an increase in the <60- and
70– to 79-years age groups. Temporal changes in excess
mortality by prefectures and pooled estimates are shown
in Supplementary Figure S5 (available as Supplementary
data at IJE online). Consistently with the country-pooled
estimates, similar waveforms were observed for
prefecture-specific estimates. The spatial distribution of
percentage excess in mortality during the period 14
January–31 December 2020 in the 47 prefectures of Japan
in total and stratified by sex and age groups are shown in
Figure 2. There was spatial heterogeneity in the excess
mortality between prefectures (Cochran Q test, p< 0.001;
I2¼ 27.3%).
The dispersion parameters, plots of model residuals, ob-
served and fitted time-series plots, autocorrelation and par-
tial autocorrelation function of the residuals suggested that
our model had an adequate amount of adjustment for sea-
sonal trends (Supplementary Figures S1–S4, available as
Supplementary data at IJE online). We also performed sen-
sitivity analyses to evaluate whether these findings were
sensitive to the levels of control for influenza activity, am-
bient temperature and the number of knots (four, five and
six) in the interrupted spline component. The sensitivity
analysis revealed that the temporal changes in excess mor-
tality were consistent with the main analysis and the
obtained curves identify the pandemic as one continuous
until November, rather than small waves that clearly de-
pend on the number of knots chosen (Supplementary
Figure S6, available as Supplementary data at IJE online).
The estimates of excess deaths and percentage excess
obtained using sensitivity analyses are reported in
Supplementary Tables S3–S8 (available as Supplementary
data at IJE online). The QAICs for the main model and
each sensitivity analysis are reported in Supplementary
Table S9 (available as Supplementary data at IJE online).
The sensitivity analysis found that total excess deaths
ranged between 28 834 (95% eCI: 33 025 to 24 510)
and 18 476 (95% eCI: 24 939 to 11 957), correspond-
ing to a percentage excess of 2.4 (95% eCI: 2.7 to
2.0) and 1.5 (95% eCI: 2.1 to 1.0).
Discussion
We estimated the all-cause excess mortality during the
COVID-19 outbreak in Japan using a two-stage inter-
rupted time-series design and flexible statistical methods.
Figure 1 Trends in estimated excess risk (relative risk) during the period 14 January–31 December 2020 in Japan by sex and age groups compared
with the total (band corresponds to 95% empirical confidence intervals)
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Our models revealed a decrease in mortality during the
COVID-19 outbreak in February–December 2020 in
Japan. There was significant spatial heterogeneity between
prefectures. The difference in the methods between our
study and the previous study in Italy is that our study con-
sidered the effects of influenza activity in the main model,
whereas the previous study did not.
Our findings showed that the COVID-19 outbreak may
have potentially led to a decrease in deaths in Japan. These
results align with a recent study that indicated a much
lower overall excess-mortality burden due to COVID-19 in
Japan than in Europe and the USA.14 However, that study
used weekly data on a shorter period and used data for
3 weeks before and after a certain point as the reference
Figure 2 The spatial distribution of percentage excess in mortality during the period 14 January–31 December 2020 in the 47 prefectures of Japan in
total and stratified by sex and age groups






/ije/advance-article/doi/10.1093/ije/dyab216/6413683 by London School of H
ygiene & Tropical M
edicine user on 01 D
ecem
ber 2021
period. Additionally, the study did not consider variations
in the effect of influenza activity and ambient tempera-
ture.14 In contrast, an advantage of our study is that we
used an advanced two-stage interrupted time-series design
based on daily data and considering temporal trends and
variations in these confounding factors. During the first
wave of the COVID-19 epidemic in Japan, the Japanese
government was criticized because of not performing re-
verse transcriptase–polymerase chain reaction (RT-PCR)
tests extensively26 and the very small number of COVID-
19 deaths was considered due in part to under-reporting of
COVID-19 mortality. However, our results indicated that
the total excess risk of mortality in Japan started decreas-
ing below the baseline since the first COVID-19 case was
confirmed and continued to remain low. Thus, the criti-
cism that other causes were assigned to the unidentified
cases of COVID-19 is not considered to be valid. Our find-
ings suggest that Japan is one of the few countries with
negative excess mortality in the world.27
Our study revealed significant spatial heterogeneity in
excess mortality among prefectures, suggesting the exis-
tence of regional differences in the COVID-19 situation. It
is possible that regional differences may be related to
changes in people’s lifestyles, human behaviour and mor-
bidity due to movement restrictions and socio-economic
conditions during the COVID-19 outbreak.28 Regional
variations in excess mortality may be attributed to other
factors such as population density, timely access to medical
care and available beds, and cluster outbreaks in elderly-
care facilities and medical institutions.29 These factors may
have contributed to the variations in excess mortality and
further studies are essential to consider a variety of socio-
economic and demographic factors in different regions.
Several possible mechanisms have been proposed to ex-
plain this low mortality. First, influenza activity has been
at lower levels in 2020 than in previous years in Japan.30
Approximately 2000 and 12 000 fewer deaths from influ-
enza and pneumonia without COVID-19, respectively,
have been reported in 2020 compared with the same pe-
riod in 2019.31 Second, the number of road-traffic fatali-
ties decreased from January to September 2020 in Japan,
which might be due to the decrease in mobility and traffic
volumes on major national highways.32 These results
might be related to the reduction in all-cause deaths due to
COVID-19 in Japan.
Japan saw far fewer cases and a much lower incidence
rate of COVID-19 than comparable high-income coun-
tries2 and its coronavirus response was broadly consistent
with WHO best-practice guidelines. This reduced trans-
mission of the virus and relative success in protecting el-
derly populations from infection may also have driven the
low mortality rate. Regarding these points, several
hypotheses have been proposed. First, East Asian popula-
tions have a higher allele frequency of the angiotensin-
converting enzyme-2 (ACE2) variants associated with
higher tissue expression of ACE2.33 Elevated plasma
ACE2 is associated with increased risk of atrial fibrillation,
myocardial infarction, coronary artery disease, heart fail-
ure and aortic stenosis;34 thus, Japanese people may have
reduced susceptibility due to increased ACE2-receptor ex-
pression. Second, countries including Japan with the man-
datory bacille Calmette-Guérin (BCG) vaccination may
have reduced mortality for COVID-19 compared with
those that do not: among findings, BCG may boost trained
immunity35 and vaccination might be associated with a de-
crease in mortality.36 The BCG vaccine also promotes the
production and maturation of naı̈ve T cells that lead to en-
hanced long-term trained immune protection against
SARS-CoV-2.37 Furthermore, small-module BCG mimics
such as emetin and lopinavir inhibit the growth of SARS-
CoV-2 in vitro, which may contribute to reduce COVID-
19 mortality.37 Although the exact mechanisms of remain
unclear, it may result from complex and multifactorial
interactions among these and other as-yet unidentified
factors.
Stratified analysis showed a reduction in mortality in
both men and women during the COVID-19 outbreak in
Japan. Specifically, the percentage excess was 1.3% for
men and 2.5% for women, with approximately twice the
decline in women as in men. However, we found increases
in mortality in the <60-years age group from the middle of
June 2020. This finding is consistent with a recent study
which suggested that suicide rates in Japan in 2020 in-
creased in October and November in men and in July
through November in women, and that the increase was
most pronounced among males aged <30 years and in
females aged <30 as well as 30–49 years.38 Additionally,
on 1 March 2021, the Ministry of Health, Labour and
Welfare, Japan, reported that the cumulative number of
layoffs and suspensions related to the COVID-19 outbreak
had reached 90 185 as of 26 February 2021.39
Furthermore, on 16 March 2021, Japan’s National Police
Agency reported that juvenile suicides reached a record
high of 499 in 2020 since records began to be kept in
1980.40 These might be related to the fact that physical iso-
lation and lockdown affect serious threats to the mental
health and well-being of the general population.41 Public
health emergencies due to the outbreak are associated with
a range of psychosocial difficulties, including economic
and financial loss from unemployment and reduced in-
come, school and work closures, inadequate resources for
suitable medical responses, domestic violence and insuffi-
cient distribution of basic necessities.42 Loneliness as well
as social isolation also increases the risk of depression, and
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children and adolescents are more likely to experience in-
creased rates of depression and anxiety.43 Although we
could not access individual data on deaths, increased suici-
dality due to economic and mental health problems in the
<60-years age group might be related to the increase in
mortality.
Our study also showed that there were significant
increases in mortality in the 70– to 79-year age group from
February 2020 in Japan. Loneliness and social isolation in
the aged are also serious public health risks.44 Previous
studies have shown that older adults are at elevated risk
for morbidity and mortality due to COVID-19 and also
likely to experience extended isolation.45 Social loneliness
and isolation in older adults were associated with a 50%
increase in the risk of dementia46 and a 26% increase in
the risk of premature death from all causes.47 Moreover,
degraded social relationships due to social loneliness and
isolation were associated with a 30% increased risk of cor-
onary artery disease and stroke.48,49 These results suggest
that increased risk of dementia, coronary heart disease and
stroke due to social isolation might be associated with the
increase in mortality in the 70– to 79-years age group.
Although increased excess mortality was not observed in
the 60– to 69-years age group, this might be due to the fact
that many people in their 60s are working on the frontline
and are an economically active population.50 Furthermore,
depression symptoms were lower among people aged 60–
69 years compared with those aged >70 years during the
COVID-19 pandemic.51 Further more detailed analysis of
cause-specific excess mortality is needed to determine the
reason for the higher excess mortality in specific age
groups during the COVID-19 outbreak in Japan.
Our present results carry practical implications for the
clarification or adjustment of estimates for excess deaths in
public health policies for COVID-19. Our study estimates
a substantial difference in excess mortality compared with
other comparable high-income countries. Although the
Japanese government does not have legal authority to im-
pose lockdowns or to fine residents who ignore requests to
cooperate in preventing the spread of COVID-19, most
Japanese people have been following such requests. Our
findings are important because there may be no need to im-
pose strict social-distancing and social-isolation measures
for COVID-19 in Japan. Further, international fora should
be informed that the influence of COVID-19 on mortality
varies by country and region.
There are several limitations in this study. First, we
could not take account of information concerning individ-
ual factors, such as demographics or socio-economic sta-
tus, due to difficulties in sourcing data. Therefore, we did
not account for social or economic vulnerabilities in our
estimates of excess mortality. Additionally, investigating
the role of social and demographic factors in the spread of
COVID-19 would depend on data on behavioural trends
in Japan. Because COVID-19 is likely spread through both
human mobility and social transmission networks, these
clearly require future study. Second, although the vital-sta-
tistics survey is based on the Family Register Act and the
registries are considered complete, mortality data in 2020
were early-release data and there may be some differences
from the actual number of deaths. This happened due to
delays in reporting deaths from municipal governments to
the national Ministry of Health, Labour and Welfare. This
delay might be due to the overload of the health-depart-
ment workers due to the COVID-19-related work.
However, we suggest that this would not result in substan-
tial bias because the death notification must be submitted
to the municipal government within 7 days under the
Family Register Act in Japan and the degree of delayed
reporting is considered to be very low.14 Third, biases may
have resulted from our inability to consider immunity to or
the likelihood of person-to-person transmission as well as
variations in symptoms or presentation of COVID-19 in
the population at risk. Variations resulting from immunity
to as well as the transmissibility of SARS-CoV-2 in the at-
risk population may have biased our estimates. Fourth, al-
though we analysed daily data spanning from 2015 to
2020, the pandemic of COVID-19 is ongoing and our data
did not represent the full pandemic period in Japan. The
modelling accuracy of our study would be improved by a
longer study period or more detailed data. These possible
biases might have in turn influenced our interpretation of
the results and future studies with more precise modelling
methods and detailed data are required.
In summary, our present study estimated a reduction in
all-cause mortality during the COVID-19 outbreak in
2020 in Japan. Knowledge of the effects of the COVID-19
outbreak on different types of disease and areas is insuffi-
cient. Further studies with longer-term estimation of cause-
specific excess deaths during the COVID-19 outbreak are
warranted.
Supplementary data
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